Subject characteristics
Controls | Patients | |||
All | Non-CFRD | CFRD | ||
Subjects n | 26 | 50 | 37 | 13 |
Age yrs | 28.4±5.7 | 28.0±8.2 | 26.5±7.9 | 32.2±8.1¶ |
Sex male/female n | 14/12 | 33/17 | 24/13 | 9/4 |
Height m | 1.74±0.1 | 1.70±0.1 | 1.71±0.1 | 1.68±0.1 |
BMI kg·m−2 | 22.2±1.7 | 22.2±3.1 | 21.9±3.0 | 22.9±3.5 |
Total FFMI# kg·m−2 | 18.2±1.8 | 18.1±2.6 | 18.0±2.6 | 18.3±2.6 |
WHR | 0.80±0.06 | 0.85±0.08* | 0.86±0.06* | 0.83±0.13 |
FEV1 % pred | 97.4±8.5 | 65.1±21.2** | 69.4±22.0** | 52.9±12.6**,¶¶ |
FVC % pred | 97.5±10.4 | 79.6±18.6** | 83.9±18.9** | 67.2±10.6**,¶¶ |
Physical activity MET | 39 (33–62) | 42 (29–77) | 42 (29–77) | 40 (30–63) |
Biochemical measurements | ||||
Total cholesterol mmol·L−1 | 4.5±0.7 | 3.7±0.7** | 3.7±0.7** | 3.9±1.0 |
Cholesterol ratio TC/HDL | 3.1±0.7 | 3.0±0.7 | 2.9±0.8 | 3.0±0.7 |
Triglyceride mmol·L−1 | 0.7±0.3 | 0.9±0.3* | 0.9±0.3 | 0.9±0.3 |
Fasting glucose mmol·L−1 | 5.1±1.1 | 5.4±1.3 | 4.8±1.1 | 7.5±1.5**,¶¶ |
CRP mg·L−1 | 0.4±3.9 | 2.7±4.8** | 1.9±4.7** | 7.4±3.3**,¶¶ |
GFR mL·min−1 | 109.7±15.4 | 95.5±18.7** | 95.9±18.5** | 94.3±19.9* |
Data presented as mean±sd or median (range), unless otherwise stated. Fasting glucose and C-reactive protein (CRP) are presented as geometric mean±sd. CFRD: cystic fibrosis-related diabetes; BMI: body mass index; FFMI: fat-free mass index; WHR: waist-to-hip ratio; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; MET: metabolic equivalent of task; TC: total cholesterol; HDL: high density lipoprotein; GFR: glomerular filtration rate. #: in 48 patients. *: p<0.05, and **: p<0.01 difference from controls; ¶: p<0.05, and ¶¶: p<0.01 difference from non-diabetic patients.